MITO - Stealth BioTherapeutics Corp

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.47
+0.47 (+3.36%)
At close: 3:51PM EDT
Stock chart is not supported by your current browser
Previous Close14.00
Open13.97
Bid0.01 x 1100
Ask14.68 x 1300
Day's Range13.81 - 14.64
52 Week Range11.11 - 20.99
Volume2,877
Avg. Volume43,046
Market Cap506.881M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-16.95
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Trade prices are not sourced from all markets
  • Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy
    PR Newswire2 hours ago

    Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy

    "The debilitating fatigue and muscle weakness due to primary mitochondrial myopathy often has a negative impact on the quality of life of affected patients," said Dr. Michio Hirano, professor of neurology at Columbia University Medical Center in New York, who enrolled the most patients across the 28 sites involved in the trial. Approximately 40,000 individuals in the U.S. have been diagnosed with PMM, a rare primary mitochondrial disease. There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) for the treatment of PMM.

  • Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
    PR Newswire9 days ago

    Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial

    BOSTON, April 16, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced positive results from the open-label extension of the Phase 2/3 TAZPOWER study of elamipretide, an investigational drug, in patients with genetically confirmed Barth syndrome. Barth syndrome is an ultra-rare mitochondrial disease in which reduced levels of the mitochondrial phospholipid cardiolipin are associated with skeletal muscle weakness, debilitating fatigue, cardiac abnormalities, recurrent infections, delayed growth and reduced life expectancy.

  • Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights
    PR Newswire21 days ago

    Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights

    Completed initial public offering with gross proceeds of $85.1 million Dosed first patient in Phase 2b study of elamipretide in patients with dry AMD with geographic atrophy FDA interactions on Barth syndrome ...

  • Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference
    PR Newswire23 days ago

    Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference

    BOSTON , April 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases ...

  • Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD
    PR Newswire28 days ago

    Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD

    BOSTON, March 28, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has dosed the first patient in ReCLAIM-2, a Phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy.

  • Benzingalast month

    BMO Bullish On 'Blockbuster Potential' Of Stealth BioTherapeutics' Lead Candidate

    Stealth BioTherapeutics Corp (NASDAQ: MITO )'s lead drug elamipretide has “blockbuster potential” in primary mitochondrial dysfunction, or PMM, according to BMO Capital Markets. The Analyst BMO Capital ...

  • Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option
    PR Newswire2 months ago

    Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option

    BOSTON, March 4, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has issued an additional 588,232 American Depositary Shares ("ADSs") at the public offering price of $12.00 per ADS, resulting in additional gross proceeds of approximately $7.1 million, pursuant to the exercise in part of the underwriters' over-allotment option in connection with Stealth's previously announced initial public offering of ADSs. After giving effect to the partial exercise of the over-allotment option, the total number of ADSs sold by Stealth in the initial public offering was 7,088,232 ADSs and total gross proceeds, before deducting underwriting discounts and commissions and other offering expenses payable by Stealth, were approximately $85.1 million.

  • Benzinga2 months ago

    IPO Outlook For The Week: Biotechs And Another Virgin Group Addition

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Anchiano Therapeutics Ltd. (ANCN) will issue 2.4 million shares at $14.55 ...